 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
BF2.649
|
|
Mode of action:
|
H3 antagonist/inverse agonist
|
|
Phase:
|
Phase 2
|
|
Company:
|
University of Texas Southwestern
|
|
Note:
|
Add-on for cognitive disorders, shows effect in narcolepsy
|
Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP,
Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin
JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau
A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W,
Schwartz JC. BF2.649
[1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine,
hydrochloride], a nonimidazole inverse agonist/antagonist at
the human histamine H3 receptor: Preclinical pharmacology. J
Pharmacol Exp Ther . 2007 Jan ; 320(1):365-75. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: